Cancer Advisor

Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...

Evidence review updated: September 2026 Bottom line: EnteroMix is a genuine experimental Russian cancer immunotherapy, but it is not an approved cancer cure and it is not the same thing as Russia's personalized mRNA cancer-vaccine programme. EnteroMix is an oncolytic virotherapy based on four enteroviruses . As of 2026, the publicly registered human evidence remains an early Phase I study focused primarily on safety, tolerability, pharmacokinetics and dose selection. Claims of "100% efficacy," dramatic tumour regression, or a proven cancer cure go substantially beyond the publicly verifiable clinical evidence. Important: EnteroMix should not be confused with Russia's separate personalized mRNA cancer-vaccine programme. The two technologies have different mechanisms, development programmes and evidentiary status. Contents 1. What is EnteroMix? 2. The critical correction: EnteroMix is not the mRNA vaccine 3. How EnteroMix is intended to work ...

This is a supplementary article that contain the case details, sources and references for the primary compilation article . Note: The case reports below offer detailed, practical information on fenbendazole, ivermectin, and cancer that clinicians can find both useful and actionable. Fenbendazole and Ivermectin Prostate Cancer Case Series Compilation and Presentations This compilation features several case reports from multiple sources involving the use of ivermectin and/or fenbendazole for prostate cancer. Tables 1 - 3 below provide a summary of the information for the cases presented in this paper, including therapies used, dosage, outcome, and prior treatments. The cases are organised into tables grouped by primary drug emphasis (FBZ-focused (Table 1), IVM-focused (Table 2), or combinations (Table 3)). Each table includes key details: case number, patient demographics, cancer details, protocol, outcomes, and notes. Due to volume, only high-detail cases are prioritized. For details o...